Interestingly, treatment with the anti-TNFα etanercept improves airway hyperresponsiveness and quality of life in refractory asthma, and this improvement positively correlated with etanercept-induced reduction of membrane-bound TNFα expression (Brightling et al., 2008). Here, TNF is linked to airway hyperresponsiveness.